Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 12/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 10/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 10/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499535 | 0.87 | RIPK1 (0.38) | ADRB3ADRB1ADRB2CYP2D6ADRA1D | |
| SCHEMBL4755330 | 0.84 | ADRB3 (0.45) | ADRB3ADRB1ADRB2CYP2D6ADRA1D | |
| SCHEMBL27656228 | 0.82 | BACE1 (0.43) | ADRB3ADRB1ADRB2CYP2D6ADRA1D | |
| SCHEMBL499034 | 0.80 | LMNA (0.38) | CYP1A2CYP2C19 | |
| SCHEMBL9316827 | 0.76 | BACE1 (0.46) | ADRB3ADRB1ADRB2CYP2D6ADRA1D | |
| SCHEMBL27693712 | 0.76 | BACE1 (0.46) | ADRB3ADRB1ADRB2CYP2D6ADRA1D | |
| SCHEMBL8770902 | 0.76 | L3MBTL1 (0.43) | ADRB3ADRB1ADRB2CYP2D6ADRA1D | |
| SCHEMBL10318009 | 0.76 | KDM4E (0.46) | CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL7120069 | 0.76 | BACE1 (0.43) | ADRB3ADRB1ADRB2CYP2D6ADRA1D | |
| SCHEMBL7120076 | 0.76 | BACE1 (0.43) | ADRB3ADRB1ADRB2CYP2D6ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106221-B2 | Renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106221-B2 | Renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100144825-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20100144825-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
| WO-2008156816-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008156816-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144825-A1 | Renin Inhibitors | ACE, REN, DNPEP | ADRB3 1089/4885ADRB1 1050/4885ADRB2 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.